Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium
06 Dezember 2024 - 2:30PM
Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:
DRTS, DRTSW), the developer of the innovative alpha-radiation
cancer therapy Alpha DaRT®, today announced
that CFO Raphi
Levy will present at the Ladenburg
Oncology Innovators & Investors Symposium.
Event: |
Ladenburg Oncology Innovators & Investors Symposium |
Format: |
Presentation and 1-on-1 Meetings |
Date: |
December 12, 2024 |
Time: |
11:00AM – 11:25AM EST |
Location: |
Virtual |
|
|
Please reach out to your Ladenburg representative to schedule
1-on-1 meetings with Mr. Levy.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics
company that focuses on research, development, and potential
commercialization of the Alpha DaRT for the treatment of solid
tumors. The technology was initially developed by Prof. Itzhak
Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is
designed to enable highly potent and conformal alpha-irradiation of
solid tumors by intratumoral delivery of radium-224 impregnated
sources. When the radium decays, its short-lived daughters are
released from the sources and disperse while emitting high-energy
alpha particles with the goal of destroying the tumor. Since the
alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims
to mainly affect the tumor, and to spare the healthy tissue around
it.
Investor Relations Contact: IR@alphatau.com
Alpha Tau Medical (NASDAQ:DRTS)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Alpha Tau Medical (NASDAQ:DRTS)
Historical Stock Chart
Von Dez 2023 bis Dez 2024